{
    "xml": "<topic id=\"PHP6699\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/neostigmine\" basename=\"neostigmine\" title=\"NEOSTIGMINE\">\n<title>NEOSTIGMINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_647\" namespace=\"/interactions/list-of-drug-interactions/parasympathomimetics/neostigmine\">Neostigmine</xref>\n</p>\n<data name=\"vtmid\">80024007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_126257276\" title=\"Anticholinesterases\">Anticholinesterases</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34588\" title=\"ANTICHOLINESTERASES\" namespace=\"/drug-classes/anticholinesterases\">ANTICHOLINESTERASES</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n<p outputclass=\"synonyms\">Neostigmine methylsulfate</p>\r\n</body>\n<topic id=\"PHP50928\" outputclass=\"indicationsAndDose\" rev=\"1.43\" parent=\"/drugs/neostigmine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of myasthenia gravis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 15&#8211;30&#8239;mg, dose repeated at suitable intervals throughout the day, total daily dose 75&#8211;300&#8239;mg, the maximum that most patients can tolerate is 180 mg&#8239;daily.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection or by intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8211;2.5&#8239;mg, dose repeated at suitable intervals throughout the day (usual total daily dose 5&#8211;20&#8239;mg).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Reversal of non-depolarising (competitive) neuromuscular blockade</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2.5&#8239;mg (max. per dose 5&#8239;mg), repeated if necessary after or with glycopyrronium or atropine, to be given over 1 minute.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50748\" outputclass=\"unlicensedUse\" rev=\"1.7\" parent=\"/drugs/neostigmine\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p>Dose for treatment of myasthenia gravis by subcutaneous or intramuscular injection in neonate is unlicensed.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP51066\" outputclass=\"cautions\" rev=\"1.16\" parent=\"/drugs/neostigmine\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<sectiondiv outputclass=\"additionalCautions\">\n<sectiondiv outputclass=\"cautionsOrContraindicationsWithRoutes\">\n<p outputclass=\"title\">With intravenous use</p>\n<p>\n<ph outputclass=\"caution\">glycopyrronium or atropine should also be given when reversing neuromuscular blockade</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50888\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/neostigmine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (parasympathomimetics).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50838\" outputclass=\"renalImpairment\" parent=\"/drugs/neostigmine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>May need dose reduction.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP6699-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/neostigmine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76563\" title=\"Tablet\" namespace=\"/drugs/neostigmine/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76570\" title=\"Solution for injection\" namespace=\"/drugs/neostigmine/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP88068\" namespace=\"/drugs/glycopyrronium-bromide-with-neostigmine\" title=\"GLYCOPYRRONIUM BROMIDE WITH NEOSTIGMINE\" count=\"1\" rel=\"backlink\">GLYCOPYRRONIUM BROMIDE WITH NEOSTIGMINE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP97237\" namespace=\"/guidance/adverse-reactions-to-drugs\" title=\"Adverse reactions to drugs\" count=\"1\" rel=\"backlink\">Adverse reactions to drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78233\" namespace=\"/treatment-summaries/constipation\" title=\"Constipation\" count=\"1\" rel=\"backlink\">Constipation</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78426\" namespace=\"/treatment-summaries/neuromuscular-blockade\" title=\"Neuromuscular blockade\" count=\"5\" rel=\"backlink\">Neuromuscular blockade</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78500\" namespace=\"/treatment-summaries/pre-medication-and-peri-operative-drugs\" title=\"Pre-medication and peri-operative drugs\" count=\"3\" rel=\"backlink\">Pre-medication and peri-operative drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78505\" namespace=\"/treatment-summaries/neuromuscular-disorders\" title=\"Neuromuscular disorders\" count=\"4\" rel=\"backlink\">Neuromuscular disorders</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_647\" namespace=\"/interactions/list-of-drug-interactions/parasympathomimetics/neostigmine\" title=\"Neostigmine\" count=\"1\" rel=\"link\">Neostigmine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34588\" namespace=\"/drug-classes/anticholinesterases\" title=\"ANTICHOLINESTERASES\" count=\"1\" rel=\"link\">ANTICHOLINESTERASES</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76563\" namespace=\"/drugs/neostigmine/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76570\" namespace=\"/drugs/neostigmine/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP6699",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/neostigmine",
    "basename": "neostigmine",
    "title": "NEOSTIGMINE",
    "interactants": [
        {
            "id": "bnf_int_647",
            "label": "Neostigmine"
        }
    ],
    "vtmid": "80024007",
    "drugClassification": [
        "Anticholinesterases"
    ],
    "inheritsFromClass": [
        "ANTICHOLINESTERASES"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "Neostigmine methylsulfate"
    ],
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of myasthenia gravis",
                        "html": "Treatment of myasthenia gravis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection or intramuscular injection"
                    ],
                    "textContent": "By subcutaneous injection or by intramuscular injection",
                    "html": "By subcutaneous injection or by intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 15&#8211;30 mg, dose repeated at suitable intervals throughout the day, total daily dose 75&#8211;300 mg, the maximum that most patients can tolerate is 180 mg daily.",
                        "html": "<p>Initially 15&#8211;30&#8239;mg, dose repeated at suitable intervals throughout the day, total daily dose 75&#8211;300&#8239;mg, the maximum that most patients can tolerate is 180 mg&#8239;daily.</p>"
                    },
                    {
                        "textContent": "1&#8211;2.5 mg, dose repeated at suitable intervals throughout the day (usual total daily dose 5&#8211;20 mg).",
                        "html": "<p>1&#8211;2.5&#8239;mg, dose repeated at suitable intervals throughout the day (usual total daily dose 5&#8211;20&#8239;mg).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Reversal of non-depolarising (competitive) neuromuscular blockade",
                        "html": "Reversal of non-depolarising (competitive) neuromuscular blockade"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection"
                    ],
                    "textContent": "By intravenous injection",
                    "html": "By intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "2.5 mg (max. per dose 5 mg), repeated if necessary after or with glycopyrronium or atropine, to be given over 1 minute.",
                        "html": "<p>2.5&#8239;mg (max. per dose 5&#8239;mg), repeated if necessary after or with glycopyrronium or atropine, to be given over 1 minute.</p>"
                    }
                ]
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "textContent": "Dose for treatment of myasthenia gravis by subcutaneous or intramuscular injection in neonate is unlicensed.",
                "html": "<p>Dose for treatment of myasthenia gravis by subcutaneous or intramuscular injection in neonate is unlicensed.</p>"
            }
        ]
    },
    "cautions": {
        "cautionsOrContraindicationsWithRoutes": [
            {
                "type": "cautionsOrContraindicationsWithRoutes",
                "textContent": "glycopyrronium or atropine should also be given when reversing neuromuscular blockade",
                "html": "glycopyrronium or atropine should also be given when reversing neuromuscular blockade",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With intravenous use",
                    "routes": [
                        "intravenous"
                    ]
                }
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (parasympathomimetics).",
                "html": "<p>Appendix 1 (parasympathomimetics).</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "May need dose reduction.",
                "html": "<p>May need dose reduction.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76563",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76570",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drug": [
            {
                "id": "PHP88068",
                "label": "GLYCOPYRRONIUM BROMIDE WITH NEOSTIGMINE",
                "type": "drug"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP97237",
                "label": "Adverse reactions to drugs",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78233",
                "label": "Constipation",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78426",
                "label": "Neuromuscular blockade",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78500",
                "label": "Pre-medication and peri-operative drugs",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78505",
                "label": "Neuromuscular disorders",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_647",
                "label": "Neostigmine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34588",
                "label": "ANTICHOLINESTERASES",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76563",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76570",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}